Company intelligence
Median Technologies
About Median Technologies
Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and eyonis™, our AI/ML tech-based suite of software as medical devices (SaMD) help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world. Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label “Innovative company” by the BPI and is listed on Euronext Growth market (Paris). FR0011049824– ticker: ALMDT. Median is eligible for the French SME equity savings plan scheme (PEA-PME).
Verified activity
Signals from Median Technologies
4 published signals
Products & Services
Median Technologies contributes to the future of lung cancer screening with eyonis® LCS, an AI/ML-based CADe/CADx SaMD designed to support radiologists' workflow in early detection, localization, and characterization of pulmonary parenchymal nodules on low-dose chest CT images.
Reported by Median Technologies
Presence & Recognition
Median Technologies is attending the WCLC 2026 World Conference on Lung Cancer in Seoul, Republic of Korea.
Reported by Median Technologies
Strategy & Corporate Development
Median Technologies established a dedicated R&D Committee to oversee scientific and technical development priorities and support the long-term expansion of the eyonis® platform.
Reported by Median Technologies
Strategy & Corporate Development
Median Technologies established a Strategic Review Committee to identify and evaluate strategic, structural, transactional, and financing alternatives aimed at unlocking the Company’s intrinsic value and accelerating its eyonis® pan-cancer strategy.
Reported by Median Technologies